A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Grants and Contracts Details

StatusFinished
Effective start/end date3/1/19 → 12/4/19

Funding

  • Syneos Health LLC: $18,968.00